Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x100px
Organisation › Details

BEAt-DKD project (IMI, EU, EFPIA, 201702–)

Diabetic kidney disease (DKD) is the most common form of chronic kidney disease (CKD), which at present affects more than 10% of the world population. Unfortunately, there are no effective means to prevent or cure DKD. Apart from Renin-Angiotensin-Aldosterone System (RAAS) blockade, which has limited effect, very few alternative therapies have emerged. Lack of predictive and prognostic biomarkers for an accurate patient stratification, limited access to kidney tissue from patients at various stages of DKD and to appropriate model systems to better understand the pathogenesis of the disease, are likely reasons for the stagnating development of new treatments. The BEAt-DKD team, coordinated by the University of Lund, Abbvie, University Medical Center Groningen, University of Helsinki and Sanofi, is committed to deliver better stratification of patients and more effective tools for use in innovative clinical trials, resulting in improved prevention and management of DKD, i.e. steps towards precision medicine. BEAt-DKD plans build upon: (a) access to large observational prospective cohorts with comprehensive genetic analyses and rich longitudinal clinical and biochemical data and samples from patients with DKD; (b) vast expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental tools and approaches, including validated animal models of DKD for translational research; (c) extensive expertise in the development and validation of novel imaging approaches; (d) the ability to combine existing and novel datasets through effective data federation and use of systems biology approaches towards precision medicine; and (e) expertise in regulatory approval, health economics and patient engagement. BEAt-DKD will also capitalize from extensive and unique resources developed by previous IMI and FP7 projects. Results from this project are expected to translate into patient benefits and decreased societal costs associated with DKD.   BEAt-DKD participants are Lunds universitet, University of Helsinki, Academisch Ziekenhuis Groningen (University Medical Center Groningen), University of Oxford, University of Eastern Finland, University of Dundee, University of Exeter, Istituto di Ricerche Farmacologiche Mario Negri, Turun Yliopisto (University of Turku), Universitätsklinikum Freiburg, University of Bristol, University of Leeds, University of Hull, CHU Hopitaux de Bordeaux, University Clinic Erlangen, Medizinische Universität Innsbruck, Klinikum der Universität Regensburg,  Medizinische Universität Wien, Università degli Studi di Bari Aldo Moro, Lipotype, University of Michigan, Swiss Institute of Bioinformatics, JDRF International, AbbVie, Sanofi-Aventis, Astellas, Eli Lilly, Bayer Pharma, and Novo Nordisk. *


Period Start 2017-02-06 start
  Group Innovative Health Initiative (IHI JU)
Products Industry biomarker
  Industry 2 personalised medicine / precision medicine
Region Region EU (European Union)
  City n. a. 
    Address record changed: 2017-02-08
Basic data Employees n. a.
    * Document for »About Section«: Lipotype GmbH. (2/6/17). "Press Release: Launch of BEAt-DKD. An Innovative Medicines Initiative (IMI) Project for Precision Medicine in Diabetic Kidney Disease with Lipotype as Project Partner".
Record changed: 2023-07-15


Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

More documents for Innovative Health Initiative (IHI JU)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Biotech Showcase 2024 San Francisco 650x300px

» top